Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Status:
Active, not recruiting
Trial end date:
2024-05-28
Target enrollment:
Participant gender:
Summary
The usual approach group, 300 double blind random group separated PC patients currently used
the Combined Chemotherapy on ZYTIGA - abiraterone acetate tablet, film coated plus RAYOS -
prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated, it will try
to look for the relationship between the Abiraterone therapeutic efficacy and the CYP17 SNP
Genotyping, and the relationship between the Abiraterone therapeutic safety and the SULT2A1
SNP Genotyping, based on Oxford precisely sequencing drug targets' genes.
The study approach group, 300 double blind random group separated PC patients currently used
the Combined Chemotherapy on ZYTIGA - abiraterone acetate tablet plus RAYOS - prednisone
tablet, delayed release plus ORGOVYX - relugolix tablet, film coated, it will try to look for
the relationship between the Abiraterone therapeutic efficacy and the CYP17 SNP Genotyping,
and the relationship between the Abiraterone therapeutic safety and the SULT2A1 SNP
Genotyping, based on Oxford precisely sequencing drug targets' genes.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Han Xu, M.D., Ph.D., Non-Investigator, IRB Chair